Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q969Q1

UPID:
TRI63_HUMAN

ALTERNATIVE NAMES:
Iris RING finger protein; Muscle-specific RING finger protein 1; RING finger protein 28; RING-type E3 ubiquitin transferase TRIM63; Striated muscle RING zinc finger protein; Tripartite motif-containing protein 63

ALTERNATIVE UPACC:
Q969Q1; B4DN95; Q5T2I1; Q96BD3; Q96KD9; Q9BYV4

BACKGROUND:
The protein TRIM63, with alternative names such as Iris RING finger protein and Striated muscle RING zinc finger protein, is a key regulator in the ubiquitin-proteasome pathway. It targets specific muscle proteins for degradation, serving a critical function during amino acid scarcity and influencing muscle mass and function through its action on sarcomeric-associated proteins and myofibril organization.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of TRIM63 offers a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.